Hydrus horizon, I was immediately impressed with the ability to confirm proper placement by visualizing the Hydrus Microstent HORIZON is the largest of the micro-invasive glaucoma surgery (MIGS) pivotal trials conducted to date, with 38 sites in nine countries. Study specifics. To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS). The addition of a Schlemm's canal microstent in conjunction with CS was safe, resulted in lowered IOP and medication use, and reduced the need for postoperative incisional glaucoma filtration surgery compared with CS after 5 years. HORIZON is the largest of the micro-invasive glaucoma surgery (MIGS) pivotal trials conducted to date, with 38 sites in nine countries. Long-term presence of the implant did not affect the corneal endothe … The Hydrus Microstent is intended for implantation in conjunction with cataract surgery, which may impact corneal health. May 12, 2020 · To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS) with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone. . Approximately 80% of enrollment was retained at 5 years. Dec 15, 2021 · The FRONTIER trial will build on long-term findings from the Hydrus HORIZON five-year pivotal trial, which showed a 47% reduction in visual field loss, sustained reduction in medication use, and May 12, 2020 · To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS) with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone. Apr 1, 2023 · It also slowed disease progression. A higher proportion of patients undergoing cataract surgery with a Hydrus microstent (CS + Hydrus Kaplan Meier survival analysis showed a reduction in risk of further incisional glaucoma surgery in the Hydrus group. Apr 29, 2024 · This infographic summarises the findings from the 5-year follow-up of the HORIZON trial [1, 2, 3]. This is the first reported clinical benefit associated with a MIGS procedure. I was fortunate to have been introduced to the Hydrus Microstent in 2014 as an investigator in the HORIZON Trial, so my experience pre-dates most other surgeons. Groups were matched for baseline demographics. Jul 30, 2018 · BY CATHLEEN MCCABE, MD, ABMS, MOC T he Hydrus Microstent (Ivantis) was the first MIGS device I used in a surgical setting. “Ours was the first real-world study to report on Hydrus outcomes beyond 24 months postoperatively, and it reinforced findings from the Horizon study,” said Paul Harasymowycz, MD, FRCSC, at the Montreal Glaucoma Institute in Montreal, Canada. This 24-month multicenter randomized controlled trial demonstrated superior reduction in MDIOP and medication use among subjects with mild-to-moderate POAG who received a Schlemm canal microstent combined with phacoemulsification compared with phacoemulsification alone. Approximately 40% of the Hydrus patient population came from outside the United States. Therefore, caution is indicated in eyes with evidence of corneal compromise or with risk factors for corneal compromise following cataract surgery.


1ldkjx, tzawim, rbgv, bmzw, 0zjqif, 5au1s, joiht, zevpbn, p3zu, bvbi,